Fig. 1From: Low disease activity for up to 3 years after adalimumab discontinuation in patients with early rheumatoid arthritis: 2-year results of the HOPEFUL-3 StudyStudy design for the HOPEFUL-1, HOPEFUL-2, and HOPEFUL-3 studies. ADA Adalimumab, MTX MethotrexateBack to article page